Keyphrases
Peru
100%
Cusco
50%
Peruvian
49%
Hospitalized Patients
44%
Antimicrobial Resistance
35%
COVID-19
29%
High Altitude
19%
Bloodstream Infection
18%
Antibiotics
17%
Risk Factors
17%
Gram-negative Bacteria
17%
Escherichia Coli
14%
Uropathogenic E. Coli
14%
Extended-spectrum-lactamase
14%
Uropathogenic Escherichia Coli
14%
ESBL-producing
14%
Resistance Dynamics
14%
Seroprevalence
14%
Antimicrobial Susceptibility Pattern
14%
Flavus
14%
Point Prevalence Survey
14%
Rabies
14%
Non-HIV Cryptococcal Meningitis
14%
Methicillin-resistant Staphylococcus Aureus
14%
Multicenter Cohort Study
14%
Animal Health
14%
Lambda
14%
Variants of Concern
14%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
14%
Potential Threats
14%
Public Health
14%
Natural Selection
14%
Staphylococcus Aureus Bloodstream Infection
14%
COVID-19 Mortality
14%
Surgical Removal
14%
Clinical Tropical Medicine
14%
Cryptococcosis
14%
Hydatidosis
14%
Medical Treatment
14%
Cyst
14%
Abdominal
14%
Young Males
14%
Albendazole
14%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
14%
Subcapsular Liver Hematoma
14%
Fascioliasis
14%
Klebsiella Pneumoniae (K. pneumoniae)
12%
Carbapenems
11%
Resistance Pattern
10%
Carbapenem Resistance
9%
Medicine and Dentistry
Antibiotic Resistance
28%
Infection
17%
Bloodstream Infection
14%
Gram-Negative Bacteria
14%
Prevalence
14%
Cohort Analysis
14%
COVID-19
14%
Natural Selection
14%
Penicillinase
14%
Uropathogenic Escherichia Coli
14%
Extended Spectrum Beta Lactamase
14%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Cryptococcosis
14%
Human T-Lymphotropic Virus 1
14%
Tropical Disease
14%
Liver Hematoma
14%
Echinococcosis
14%
Albendazole
14%
Fascioliasis
14%
Combination Therapy
14%
Intensive Care Unit
7%
Assisted Ventilation
7%
Surgical Drainage
7%
Urinary Tract Infection
5%
Pseudomonas aeruginosa
5%
Escherichia coli
5%
Bacterium Isolate
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antibiotic Resistance
42%
Prevalence
28%
Bloodstream Infection
28%
Carbapenem Derivative
18%
Gram Negative Bacterium
17%
Antibiotics
17%
HIV
14%
Methicillin-Resistant Staphylococcus Aureus
14%
Cryptococcal Meningitis
14%
Liver Hematoma
14%
Uropathogenic Escherichia Coli
14%
Extended Spectrum Beta Lactamase
14%
Penicillinase
14%
Fascioliasis
14%
Escherichia coli
12%
Staphylococcus Aureus
7%
Cephalosporin Derivative
7%
Combination Therapy
6%
Urinary Tract Infection
5%
Antiinfective Agent
5%
Pseudomonas aeruginosa
5%
Klebsiella pneumoniae
5%
Third Generation Cephalosporin
5%